I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Infertility is an increasing problem in both developed and developing countries, with up to one in six couples requiring treatments.\[[@ref1]\] Polycystic ovary syndrome (PCOS) is present in almost one of every four women with type 1 diabetes.\[[@ref2]\] The major risk factors for infertility related to diabetes mellitus are hyperandrogenism and PCOS in women.

Conventional stimulation protocol in spite of its higher pregnancy rates increases the risk of ovarian hyperstimulation syndrome (OHSS), multiple gestations, etc., The need for simpler protocols with low risks, low cost, and maximum singleton pregnancies could be achieved by modifying stimulation protocols.

The present case highlights the successful treatment for infertility of type 1 diabetic PCOS patient using clomiphene--antagonist protocol followed by rescue *in vitro* maturation (IVM)--intracytoplasmic sperm injection (ICSI) procedures.

C[ASE]{.smallcaps} R[EPORT]{.smallcaps} {#sec1-2}
=======================================

A 32-year-old woman and her 35-year-old husband presented in 2016 with a 5-year history of primary infertility and two failed attempts of conventional *in vitro* fertilization (IVF)/ICSI. The female was a type 1 diabetic patient and the existence of bilateral polycystic ovaries was discovered by ultrasound examination. The findings of hysteroscopy were normal and the hormonal parameters were as expected (follicle-stimulating hormone \[FSH\]: 7.40 mIU/ml, luteinizing hormone: 9.89 mIU/ml, and prolactin: 15.84 ng/ml). The semen analysis showed normal semen parameters. The chromosomal analysis showed normal male and female karyotypes.

The female started an IVF program in which she was given clomiphene tablets orally for the first 5 days, and from day 7 to 13, 150 IU of recombinant FSH was administered subcutaneously. From day 8 to 14, 150 IU of menotropin and from day 10 to 14, 0.25 mg of cetrorelix were administered subcutaneously. The patient was evaluated continuously, and when leading follicle of 20 mm (only follicle) on day 15 was observed, 250 μg recombinant human chorionic gonadotropin-alpha was administered subcutaneously for triggering. After 36 h, one oocyte was collected which was found to be immature \[[Figure 1](#F1){ref-type="fig"}\] (germinal vesicle stage) when denuded. The denuded oocyte was subjected to rescue IVM for 25 h (until the extrusion of the first polar body) in culture medium (Vitrolife^®^, Goteborg, Sweden). The matured oocyte \[[Figure 2](#F2){ref-type="fig"}\] (metaphase II) was injected with the husband sperm after processing the semen by swim-up method. Two pronuclei \[[Figure 3](#F3){ref-type="fig"}\] were seen 18 h post-ICSI and a grade 1 embryo \[[Figure 4](#F4){ref-type="fig"}\] was generated on day 3. A successful pregnancy was achieved. Fetal cardiac activity was noted from 6 weeks\' gestational age. The patient developed gestational hypertension which along with the diabetes was managed optimally with antihypertensives and insulin, respectively. As the patient developed preeclampsia at 32 weeks, pregnancy was terminated by a safe cesarean section and a healthy male infant (birth weight 2200 mg) was delivered.

![Obtained germinal vesicle oocyte after denudation](JHRS-11-75-g001){#F1}

![MII oocyte after *in vitro* maturation](JHRS-11-75-g002){#F2}

![Two pronuclei stage](JHRS-11-75-g003){#F3}

![Transferred day 3 embryo](JHRS-11-75-g004){#F4}

D[ISCUSSION]{.smallcaps} {#sec1-3}
========================

Diabetes mellitus in female is associated with disturbed ovarian function, but strict metabolic control may encourage the resumption of ovulation and allow ovarian stimulation for assisted reproductive technology.\[[@ref3]\] The protocol involving clomiphene citrate (CC), human menopausal gonadotropin (hMG), and cetrorelix helps women with PCOS as the incidences of moderate and severe OHSS are reduced.\[[@ref4]\] It is evident that CC/hMG protocol has resulted in a significantly lower incidence of severe OHSS when compared to GnRA long protocol.\[[@ref5]\] Moreover, it was also suggested that protocol involving gonadotropin-releasing hormone (GnRH) antagonist plus mild doses of exogenous gonadotropins and oral compounds such as CC or aromatase inhibitors was more patient friendly.\[[@ref6]\] Similarly, a chronic low-dose regiment of gonadotropins in PCOS patients has completely eliminated the troublesome complications of OHSS and also reduced the multiple pregnancy rates to a reasonable minimum.\[[@ref3][@ref7]\] Therefore, modifications in stimulation protocol for patients with PCOS can overcome the risks of OHSS, and the side effects are less as the medication is administered only for a few days.

A pregnancy using immature oocytes in nonstimulated cycles was achieved, in 1994, where the IVM period was 43--54 h.\[[@ref8]\] In another study, oocytes retrieved using nonstimulated cycles were *in vitro* maturated for 24--48 h.\[[@ref9]\] Hence, IVM requires the maturation of oocytes in the laboratory for ≥24 h before insemination, and there is a need for monitoring maturity of immature oocytes periodically during the maturation time.\[[@ref10][@ref11]\]

Characteristic features of PCOS such as hyperandrogenism, obesity, insulin resistance, and metabolic abnormalities may contribute to the increased risks of obstetrical and neonatal complications, and those patients are prone to pregnancy-induced hypertension, preeclampsia, and preterm birth suggesting cesarean section.\[[@ref12][@ref13]\]

There are many reports on successful live births using IVM--IVF procedures that have \~ 50% maturation rates and \~ 60% fertilization rates, but the number of live births was comparatively low.\[[@ref14][@ref15][@ref16][@ref17][@ref18]\] A pregnancy rate of 27.1% was achieved after IVM--IVF by transferring 6.3 embryos per patient.\[[@ref19]\]

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

Rescue IVM--ICSI is an important tool at certain circumstances in the treatment of women with PCOS and diabetes which can result in pregnancy and live birth. It is also acceptable that the modified approach involving GnRH antagonist, CC, and hMG is an effective ovarian stimulation protocol which also holds good with poor responder women and serves as a patient-friendly protocol as duration of gonadotropin injection is shorter.\[[@ref20]\]
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